Skip Navigation


NDT Advance Access originally published online on April 15, 2009
Nephrology Dialysis Transplantation 2009 24(8):2598-2600; doi:10.1093/ndt/gfp148
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/8/2598    most recent
gfp148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Skalli, S.
Right arrow Articles by Vuillez, J.-P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skalli, S.
Right arrow Articles by Vuillez, J.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy

Saadia Skalli1, Marie-Dominique Desruet1, Jean-Cyril Bourre2, Jean-Pierre Caravel2 and Jean-Philippe Vuillez2

1 Pharmacy Department 2 Nuclear Medicine Department, Hospitalo-University Center of Grenoble, Grenoble, France

Correspondence and offprint requests to: Saadia Skalli; E-mail: SSkalli{at}chu-grenoble.fr



  Abstract

One of the current therapeutic approaches in the treatment of osteoblastic bone metastases uses the affinity of Samarium (153Sm) ethylene-diamine-tetramethylene phosphonic acid (EDTMP) for bone areas of bone turnover. As Samarium EDTMP is a β-emitter, the radiotherapy contributes to osteoblastic bone lesion control over time. To date, the safety and effectiveness of Samarium therapy have not been established in patients with renal impairment. In this first report, we describe our experience of use of Samarium EDTMP in conjunction with biphosphonates in a haemodialysis patient for treatment of painful bone metastasis. Encouraging results were obtained in achieving pain control. The use of this radioisotope could be more widely applied to treat haemodialysis patients.

Keywords: bone metastases; haemodialysis patient; multiple myeloma; Samarium EDTMP

Received for publication: 4.12.08
Accepted in revised form: 12. 3.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.